This study investigates the effects of imatinib therapy on children with neurofibromatosis type 1 (NF1) who have airway-related plexiform neurofibromas. Plexiform neurofibromas are a type of tumor that can grow in various parts of the body, including the airway. The study aims to see if these specific tumors are more sensitive to imatinib, which is a type of treatment, and if it can improve breathing problems in these children.
Participants in the study will undergo tests to measure their lung function and sleep quality. These tests will help determine if the imatinib therapy is effective in improving their respiratory health. Complex terms like 'pulmonary function tests' are used to describe tests that check how well the lungs are working. Sleep studies evaluate how well someone sleeps and if they have any breathing problems during sleep.
- Who can participate: Children with neurofibromatosis type 1 (NF1) and symptomatic airway plexiform neurofibromas, as shown by abnormal sleep or lung function tests, can participate. They must be able to take medication orally or through a feeding tube and have adequate organ function.
- Study details: Participants will be required to take an investigational medication, imatinib, and will have their respiratory function monitored through specific tests. A placebo, which is an inactive substance that looks like the investigational medication but contains no medicine, is not mentioned in this study.
